Mauricio Silva, Angel Moya, Marina Berenguer, Fernando Sanjuan, Rafael López‐Andujar, Eugenia Pareja, Rodrigo Torres‐Quevedo, Victoria Aguilera, Eva Montalva, Manuel De Juan, Angelo Mattos, Martín Prieto, José Mir – 29 September 2008 – Orthotopic liver transplantation (OLT) selection for patients with hepatocellular carcinoma (HCC) is a matter of debate. The Milan criteria (MC) have been largely adopted by the international community.

Amy A. Dan, Zobair M. Younossi – 29 September 2008

Minna Ilmakunnas, Eija M. Tukiainen, Ari Rouhiainen, Heikki Rauvala, Johanna Arola, Arno Nordin, Heikki Mäkisalo, Krister Höckerstedt, Helena Isoniemi – 29 September 2008 – High mobility group box 1 protein (HMGB1), a cytokine actively secreted by phagocytes and passively released from necrotic cells, is an inflammatory mediator in experimental hepatic ischemia/reperfusion injury. We characterized its expression in human liver transplantation.

John G. O'Grady – 29 September 2008

Ashokkumar Jain, Vrishali P. Patil, John Fung – 29 September 2008

Edward J. Gane – 29 September 2008

John R. Lake – 29 September 2008

Norah A. Terrault – 29 September 2008

Natasha Halasa, Michael Green – 29 September 2008

Bret J. Spier, Patrick R. Pfau, Katelin R. Lorenze, Stuart J. Knechtle, Adnan Said – 29 September 2008 – Bile duct stones and casts (BDS) after liver transplantation are associated with significant morbidity. Risk factors for BDS formation and the efficacy of treatment in liver transplant recipients have not been systematically studied. The aim of this study was to evaluate potential risk factors for the formation of BDS in patients post–liver transplant.